| First Author | He J | Year | 2016 |
| Journal | Nat Med | Volume | 22 |
| Issue | 9 | Pages | 991-3 |
| PubMed ID | 27500725 | Mgi Jnum | J:240333 |
| Mgi Id | MGI:5883157 | Doi | 10.1038/nm.4148 |
| Citation | He J, et al. (2016) Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus. Nat Med 22(9):991-3 |
| abstractText | Systemic lupus erythematosus (SLE) is a potentially life-threatening autoimmune disease characterized by altered balance of activity between effector and regulatory CD4(+) T cells. The homeostasis of CD4(+) T cell subsets is regulated by interleukin (IL)-2, and reduced production of IL-2 by T cells is observed in individuals with SLE. Here we report that treatment with low-dose recombinant human IL-2 selectively modulated the abundance of regulatory T (Treg) cells, follicular helper T (TFH) cells and IL-17-producing helper T (TH17) cells, but not TH1 or TH2 cells, accompanied by marked reductions of disease activity in patients with SLE. |
